bold = Main text
     Part,  Chapter, Paragraphgrey = Comment text

1 II, 5. 9. 4 | wheeze (1.34 to 0.98:1 P <0.0002), asthma (1.74 to 1.02:1 2 III, 10. 2. 1 | 083 , 22/03/2006 P. 00140015.~[http://eur-lex.europa. 3 III, 10. 2. 1 | Journal L 052 , 22/02/2001 P. 00190025.~http://eur-lex.europa. 4 III, 10. 2. 1 | Journal L 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.europa. 5 III, 10. 2. 1 | do?uri=OJ:L:2007:273:0001:0030:EN:PDF]~ ~European Council ( 6 III, 10. 2. 1 | 404 , 30/12/2006 P. 00260038.~[http://eur-lex.europa. 7 III, 10. 2. 1 | 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.europa.eu/ 8 III, 10. 2. 1 | Journal L 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex. 9 III, 10. 2. 1 | 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex.europa. 10 IV, 13. 2. 2 | 616 544 for males, and 579 006 for females, respectively. 11 II, 5. 9. 4 | nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was also increased 12 II, 5. 9. 4 | symptoms (2.4, 1.3-4.6, P=0.008). Among common occupations, 13 II, 9. 3. 1 | 263; doi:10.1136/sti.2004.009415~ ~Forsgren L, Beghi E, Õun 14 III, 10. 2. 1 | 04_scenihr/docs/scenihr_o_013.pdf~ ~European Network for 15 II, 5. 5. 3 | the incidence rate is 0.016 to 0.042% with a broad variation 16 II, 5. 5. 3 | value reported for Norway (0.0164). On the other hand, data 17 IV, 13. 2. 3 | acrylamide~ ~ ~ ~<300~ ~STEC 0175 (5)~PAHs (5) other substances~ ~ 18 II, 4. 2 | regression coefficient equals -.020, which implies that if life 19 III, 10. 4. 3 | International Lakes. EUR/ICP/EHCO 020205/8Fin, 18 October 1999. Available 20 II, 5. 2. 7 | 10.1016/j.ypmed.2008.01.023] (accessed on 17 March 2008).~ 21 II, 9. 5. 4 | screening guidelines (COM (2003) 0230, Proposal for a Council 22 II, 4. 2 | regression coefficient equals -.024, implying that convergence 23 II, 5. 8. 5 | of 10+ pack-years (n=11,027). After a minimal antismoking 24 II, 5. 11. 3 | NMSC (19 600 in men and 19 029 in women). During this period, 25 III, 10. 4. 2 | were found in trouts: 0.02µg/g fish based on a TDI (Tolerable 26 III, 10. 4. 2 | 2005.pp. 156. ISBN: 92-9199-030-2.~ ~EFSA (2005): Summary 27 III, 10. 2. 1 | subjects (22,924 women and 13,031 men) who participated in 28 II, 7. 7 | a safer Europe. COM/2006/0328 of June 23, 2006 (CELEX-Nr. 29 II, 4. 2 | regression coefficient equals -.034, implying that convergence 30 II, 9. 3. 3 | C 271 E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires 31 II, 9. 3. 3 | E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires 32 II, 5. 5. 3 | incidence rate is 0.016 to 0.042% with a broad variation 33 III, 10. 4. 2 | European Communities No. L 043, 14 February 1997. Available 34 II, 6. 3. 3 | Risk factors~ ~In 2005, 28 044 HIV diagnoses were reported 35 II, 5. 9. 4 | 1989 (n=3,390), 1994 (n=4,047), 1999 (n=3,540) and 2004 ( 36 IV, 11. 1. 5 | score for each practice of 1,050 points, with scores of individual 37 III, 10. 2. 1 | healthpromotion/conferences/6gchp/hpr_050829_%20BCHP.pdf].~ ~World Health 38 II, 5. 9. 4 | 3, 95% CI 1.0-11.1, P=0.051). The population-attributable 39 III, 10. 2. 1 | relevance):~Official Journal L 052 , 22/02/2001 P. 0019 – 0025.~ 40 II, 5. 2. 6 | meta-analysis of data from 90,056 participants in 14 randomised 41 III, 10. 3. 2 | sensitisation can be as low as 0.05μg/m3 air for previously sensitised 42 III, 10. 6. 2 | socio_economics/documents/ev_060302_rd06_en.pdf].~ ~ ~ ~ 43 III, 10. 4. 2 | pp. 157~ISBN: 978-92-9199-064-1~ ~EFSA (2006c): Summary 44 II, 5. 3. 6 | European countries on 2 699 086 adult cancer cases that 45 II, 6. 3. 4 | SARS-CoV had resulted in 8 098 SARS cases in 26 countries, 46 IV, 12. 10 | residues regulations~S.I. 910 0f 2005 - food & feed hygiene 47 II, 5. 5. 3 | from 4 per 10,000 to 66 per 10000 children in the last 20 48 II, 5. 6. 6 | fractures. Am.J Epidemiol 137:1001-1005~Cooper C, Melton LJ, 49 II, 5. 7. 3 | 1209 pmp) and in Canadians (1003 pmp) (U.S. Renal Data System, 50 II, 5. 5. 3 | epilepsy. Neurology 63:1002-1007.~Sidenvall R, Forsgren L, 51 III, 10. 2. 1 | Clinical Nutrition 58, 1000-1010~Greece~Data not available~ ~ ~ ~ ~ 52 II, 5. 5. 3 | in Estonia. Epilepsia 40:1011-1019.~Berg AT, Shinnar S ( 53 II, 5. 8. 7 | Eur Respir J 2007; 30: 993–1013~ ~Vrbica (2007): COPD 54 II, 5. 7. 7 | Intern Med 2007 Jul;22(7):1018-23.~Smith DH, Gullion CM, 55 II, 5. 5. 3 | Estonia. Epilepsia 40:1011-1019.~Berg AT, Shinnar S (1991): 56 II, 5. 6. 6 | diseases. J Rheumatol 19:1020-1030~Sernbo I, Johnell O ( 57 III, 10. 5. 1 | Abnormal Child Psychology 35(6):1021-33.~Brenner BL et al, (2003): 58 II, 5. 5. 3 | InterScience DOI: 10.1002/eat.1022.~Levey R (2006): Anorexia 59 III, 10. 5. 1 | In: Ann. N.Y. Acad. Sci. 1023: 308-322 (2004).~Em M (1998): 60 II, 5. 5. 3 | epileptic seizure. Epilepsia 42:1025-1030.~Loiseau J, Loiseau 61 II, 5. 2. 7 | life. Arch Intern Med 165:1028-34.~EUROCISS Project Research 62 II, 5. 5. 3 | really exist? J Neurol 246:1033–1040.~Ford HL, Gerry E, 63 III, 10. 2. 1 | Related Metabolic Disorders 26:1036-1045.~ ~Savva SC, Tornaritis 64 III, 10. 2. 4 | online 1 April 2008; doi:10.1038/nrg2360: 2-7.~ ~Roberts, 65 II, 5. 6. 6 | Association. Arthritis Rheum 29:1039-1049~Anderson JA (1986) 66 II, 5. 5. 3 | exist? J Neurol 246:1033–1040.~Ford HL, Gerry E, Airey 67 III, 10. 2. 5 | Psychol Psychiatry 2007;48:1042-50.~ ~Mäntymaa M, Puura 68 III, 10. 2. 1 | Metabolic Disorders 26:1036-1045.~ ~Savva SC, Tornaritis 69 II, 5. 6. 6 | Arthritis Rheum 29:1039-1049~Anderson JA (1986) Epidemiological 70 IV, 12. 10 | system (resolution number 105136/GG 907B/17-06-04) for the 71 II, 5. 9. 7 | Questionnaire survey. BMJ 2004; 328:1052-1053.~ ~Baiardini I, Braido 72 II, 5. 9. 7 | survey. BMJ 2004; 328:1052-1053.~ ~Baiardini I, Braido F, 73 II, 5. 5. 3 | study. Mult Scler 13(8):1054-64. Erratum in: Mult Scler. 74 II, 5. 15. 6 | Pediatrics, 1978;62(6):1056-1060.~Kesselman I, Elstein 75 II, 5. 7. 3 | patients pmp in Romania to 1057 patients pmp in Germany ( 76 II, 5. 5. 3 | categories. Epilepsia 37:1051-1059.~Pazzaglia P, Frank-Pazzaglia 77 IV, 11. 6. 5 | Assessment in Health Care 16(4): 1061-76.~ ~Rizzo J, Blumenthal 78 II, 5. 5. 3 | for epilepsy. Epilepsia 38:1062-1068.~Nilsson L, Ahlbom 79 II, 5. 5. 3 | epilepsy. Epilepsia 38:1062-1068.~Nilsson L, Ahlbom A, Farahmand 80 II, 5. 9. 7 | Committee. Eur Respir J 2002; 20:1071-1079~ ~Fasce L, Tosca MA, 81 II, 5. 9. 7 | Eur Respir J 2002; 20:1071-1079~ ~Fasce L, Tosca MA, Silvestri 82 II, 5. 5. 3 | study. Epilepsia 43:1076-1083.~Beghi E (2004): Aetiology 83 II, 5. 5. 3 | clinical trial. The Lancet 371: 1085-1097.~Klosterkötter J (2007): 84 III, 10. 1. 3 | Sports Exerc 29(8):1076-1089.~Kuntsche E, Jordan MD ( 85 II, 5. 3. 5 | by sex A) Men~Figure 5.3.10b. Trends of colorectal cancer ( 86 IV, 12. 10 | May;~Portaria nb 174/97 of 10March~Despacho nb 242/96 of 13 87 II, 5. 9. 7 | Respir.Sep; 23 (4 Pt 2):10S73-10S75~ ~Bousquet PJ, Hooper R, 88 III, 10. 4. 2 | in food amounts~to about 10x that of~benzo(a)pyrene~EU 89 II, 5. 5. 3 | not, was 72%, while the 10y survival rate was 42% and 90 II, 5. 5. 3 | has been implementing a 10yrASD Strategic Action Plan 91 II, 5. 8. 7 | population. Chest 2004; 126; 1093-1101.~ ~V . (2007): Definition, 92 III, 10. 2. 1 | comparison. BMJ, 2000; 320(7242): 1102-1107.~ ~CDC (2004): 2004 93 III, 10. 1. 3 | filebank/files/20080109$110739$fil$mZ8UVQv2wQFShMRF6cuT. 94 II, 5. 5. 3 | and incident cohort~4001~1109.0~3.6~Nilsson et al, 1997~ 95 III, 10. 2. 1 | Related Metabolic Disorders 24:1111–1118.~ ~Novakova J (2006): 96 II, 5. 10. 7 | Toxicol. 2007 Jul;45(7):1116-22. Epub 2007 Jan 9.~ ~Woods 97 III, 10. 2. 1 | Metabolic Disorders 24:1111–1118.~ ~Novakova J (2006): Antropometrické 98 II, 5. 11. 7 | population. Cancer 2000;89:11211133.~ ~De Vries E, Bray 99 II, 5. 5. 3 | Arch Gen Psychiatry 64(10):1123-31.~Sartorius N (2007): 100 III, 10. 3. 2 | Environm. Hlth. Perspec. 113, 1125-1133.~ ~Bundesinstitut für 101 II, 5. 8. 7 | rural men. Chest 2006; 130: 1129-1137.~ ~Rea H, McAuley S, 102 II, 5. 12. 7 | Multi-centre group. J Hepatol 30:1130-1137.~ ~Ramstedt M (2001): 103 II, 5. 11. 7 | advantaged? Br Med J 1994;308:1132-35.~ ~Williams HC, Burney 104 II, 5. 6. 6 | organization. Arthritis Rheum 38:1134-1141~Ollier WE, Harrison 105 II, 9. 3. 1 | Inf. 80;255-263; doi:10.1136/sti.2004.009415~ ~Forsgren 106 III, 10. 2. 1 | Public Health Nutrition 10:1138-1144.~ ~Ministry of Health 107 II, 5. 10. 7 | admissions data. BMJ 327:1142-1143~International Life 108 II, 5. 10. 7 | admissions data. BMJ 327:1142-1143~International Life Sciences 109 III, 10. 2. 1 | Health Nutrition 10:1138-1144.~ ~Ministry of Health and 110 IV, 11. 6. 5 | Science and Medicine 53: 1149-1162.~ ~Goldfarb NI, Maio 111 III, 10. 2. 1 | British Medical Journal 308:1153–1156.~ ~Pudule I, Jēce I, 112 III, 10. 2. 1 | Medical Journal 308:1153–1156.~ ~Pudule I, Jēce I, Velika 113 II, 5. 2. 6 | Study). J Hypertens 14: 1159-1166.~Lewington S, Whitlock 114 IV, 11. 6. 5 | Science and Medicine 53: 1149-1162.~ ~Goldfarb NI, Maio V et 115 II, 5. 8. 7 | Burden of Airway Disease. 10.1164/ rccm.167.5.787. Am.J.Resp. 116 II, 5. 2. 6 | Study). J Hypertens 14: 1159-1166.~Lewington S, Whitlock G, 117 II, 5. 5. 3 | disease. Eur J Neurol 13(11):1170-1185.~Hughes AJ, Daniel 118 III, 10. 2. 1 | of Clinical Nutrition 60:1174-1179.~ ~Grabauskas V, Klumbienė 119 III, 10. 5. 1 | environment. Lancet 29;370(9593): 1175-87~ ~Wright AJ, et al (2005): 120 III, 10. 2. 1 | COUNCIL REGULATION (EC): No 1182/2007 of 26 September 2007 121 III, 10. 2. 1 | Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~Data not available~ ~ ~ ~ ~ 122 III, 10. 5. 1 | Lancet. 2002 Oct 19;360(9341):1184-5.~Daisey JM, Angell WJ 123 II, 5. 5. 3 | Eur J Neurol 13(11):1170-1185.~Hughes AJ, Daniel SE, Kilford 124 II, 5. 5. 3 | difficulty. Epilepsia 36:1187-1194.~Nashef L, Walker F, 125 II, 5. 6. 6 | Assess Health Care 16(4):1193-200~Juni P, Dieppe P, Donovan 126 II, 5. 5. 3 | difficulty. Epilepsia 36:1187-1194.~Nashef L, Walker F, Allen 127 III, 10. 2. 1 | Health Nutr 5 (6B), 1179-1196.~ ~ ~EFCOSUM Group (2002): 128 II, 5. 3. 5 | sex B) Women~ ~Figure 5.3.11a. Colorectal cancer (ICD9 129 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.11b. Colorectal cancer (ICD9 130 III, 10. 3. 1 | dwellings leads to 100 to 1200 extra cases of lung cancer 131 III, 10. 4. 2 | Health Perspectives 112(12): 1204-1207~ ~Kallenborn, R. and 132 II, 8. 2. 1 | carried out in a cohort of 12058 children followed up to 133 II, 5. 7. 3 | than that in US whites (1209 pmp) and in Canadians (1003 134 III, 10. 2. 1 | Sweden~RIKSMATEN~1997-1998~1210~17-79~Individual dietary 135 II, 9. 3. 3 | subsequent condom use. Aids 19:1215-23.~Layte R, McGee H, Qual 136 III, 10. 2. 5 | behavior. Child Dev 2007;78:1222-39.~ ~Barker DJP, Osmond 137 III, 10. 2. 1 | Health Nutr 5 (6B), 1217-1226.~ ~Linseisen J, Bergstrom 138 III, 10. 2. 1 | Health Nutr 2002 Dec, 5 (6B): 1227-1242.~ ~Linseisen J, Kesse 139 II, 5. 2. 7 | Europe. Eur Heart J 18: 123148.~Sarti C, Stegmayr B, 140 II, 5. 9. 7 | Immunol. 2003 Jun;111(6):1232-8~ ~von Mutius (2006): The 141 II, 5. 5. 3 | MR review and examination~1233 ~6.3 ~Keranen et al., 1989 (*)~ 142 II, 5. 5. 3 | Environ Health Perspect 113(9):1234-1238.~McCrone P, Allcock 143 II, 9. 3. 1 | and Health, Finland, ISSN 1236-2050, 2007:2) ISBN 978-952- 144 III, 10. 2. 1 | British Medical Journal 320:12401243.~ ~Currie C, Roberts 145 III, 10. 2. 1 | Nutr 2002 Dec, 5 (6B): 1227-1242.~ ~Linseisen J, Kesse E, 146 III, 10. 2. 4 | tumors. Am J Pathol, 158:1245-1251.~ ~Ibarreta D, Bock, A.K., 147 III, 10. 5. 1 | schoolwork by children (1257-RP).~ ~Walinder R, Gunnarsson 148 III, 10. 2. 1 | Nutr 2002 Dec, 5 (6B):1243-1258.~ ~Linseisen J, Rohrmann 149 II, 5. 10. 7 | allergen labelling? Allergy 59:1262-8.~ ~Mills ENC, Mackie AR, 150 II, 5. 5. 3 | childhood. Pediatrics 107:1259-1263.~Cockerell OC, Eckle I, 151 II, 5. 2. 6 | of statins. Lancet 366: 1267-1278.~Lewington S, Clarke 152 II, 5. 6. 6 | disease in farmers. BMJ 304:1269-1272~Cummings SR, Nevitt 153 II, 5. 4. 8 | Diabetes Care. 2003 Apr;26(4):1270-6.~Greenfield S, Nicolucci 154 II, 5. 6. 6 | in farmers. BMJ 304:1269-1272~Cummings SR, Nevitt MC, 155 III, 10. 2. 1 | Public Health Nutr 5 (6B): 1273-1285.~ ~ ~ 156 II, 5. 5. 3 | in children. Epilepsia 38:1275-1282.~Fisher RS (2000): 157 II, 9. 4. 7 | Biol Sci Med Sci, (12), p.1277-84.~DECODE study group on 158 II, 5. 2. 6 | statins. Lancet 366: 1267-1278.~Lewington S, Clarke R, 159 II, 5. 5. 3 | children. Epilepsia 38:1275-1282.~Fisher RS (2000): Epilepsy 160 III, 10. 2. 1 | Health Nutr 5 (6B): 1273-1285.~ ~ ~ 161 III, 10. 2. 1 | Health Nutr 2002 Dec, 5 (6B): 1287-1296.~ ~Welch AA, Lund E, 162 II, 5. 2. 6 | disease. N Engl J Med 345: 1291-1297.~ ~ 163 II, 5. 2. 6 | N Engl J Med 345: 1291-1297.~ ~ 164 IV, 12. 10 | health~ high~o The direction 1299/2003 of the Ministry of 165 II, 5. 3. 5 | by sex A) Men~Figure 5.3.12b. Trends of colorectal cancer ( 166 II, 5. 6. 6 | quality of life. Am J Med 103:12S-17S~Cooper C, Atkinson EJ, Jacobsen 167 III, 10. 2. 1 | starting on average just after 12½ years of age. Data from 168 II, 5. 7. 7 | Soc Nephrol 2004 May;15(5):1300-6.~Stengel B, Billon S, 169 I, 2. 4. 0(1) | PREREL_YEAR_2009_MONTH_02/2-13022009-EN-AP.PDF]~ 170 III, 10. 3. 1 | Reference: ISO/TC 43/SC 1 N 1313.~Kempen EEMM van, Kruize 171 III, 10. 2. 1 | Australia. Addiction, 99: 1315-1322.~ ~European Monitoring 172 III, 10. 2. 1 | Australia. Addiction, 99: 1315-1322.~ ~European Monitoring Centre 173 II, 5. 4. 8 | Acad Sci U S A. 14;104(33):13225-31~TRIG p (2007): Study 174 II, 5. 6. 6 | population. Arthritis Rheum 33:1323-1332~Kanis JA, Johnell O, 175 IV, 12. 10 | Gender issues~ high~o Law 1329/1983: Modernization of the 176 II, 5. 6. 6 | Arthritis Rheum 33:1323-1332~Kanis JA, Johnell O, Oden 177 II, 5. 10. 7 | research: a review. Allergy 61,1336-1343.~ ~European Commission ( 178 IV, 12. 10 | 2006 a Screening Decree (1339/2006) which took effect 179 II, 5. 10. 7 | review. Allergy 61,1336-1343.~ ~European Commission ( 180 II, 5. 8. 7 | COPD. Respir Med 2006; 100: 1349-1355.~ ~Viegi G, Pedreschi 181 II, 5. 8. 7 | Respir Med 2006; 100: 1349-1355.~ ~Viegi G, Pedreschi M, 182 II, 5. 5. 3 | on Aging. Neurology 55(9):1358-1363.~Benito-Leon J, Bermejo-Pareja 183 IV, 12. 10 | o Ministerial Decision 13588/725/2006Measures, terms 184 II, 5. 5. 3 | Aging. Neurology 55(9):1358-1363.~Benito-Leon J, Bermejo-Pareja 185 III, 10. 2. 1 | Icelanders 2002~DOI~2002~1366~15-80~24-hour recall~1~The 186 II, 5. 6. 6 | population study. J Rheumatol 28:1369-1377~Birnbaum HG, Barton, 187 II, 5. 8. 7 | finding study. BMJ 2002; 324: 1370-1374.~ ~Vermeeren MA, Creutzberg 188 II, 5. 8. 7 | study. BMJ 2002; 324: 1370-1374.~ ~Vermeeren MA, Creutzberg 189 II, 5. 6. 6 | study. J Rheumatol 28:1369-1377~Birnbaum HG, Barton, M, 190 II, 5. 4. 3 | ranging between 10 (Italy) and 1380 (Slovak Republic).~The annual 191 II, 5. 6. 6 | fractures. J Bone Miner Res 15:1384-1392~Oliveria SA, Felson 192 II, 5. 5. 3 | population-based study. Epilepsia 40:1388-1392.~Massey EW, Schoenberg 193 III, 10. 5. 1 | Number 11, November 1998, pp. 1389-1396(8)~ ~European Child 194 III, 10. 5. 1 | November 1998, pp. 1389-1396(8)~ ~European Child Safety 195 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.13b. Lung cancer (ICD9 162) 196 II, 8. 2. 1 | Journal of Public Health 13S: 101-6.~Lennox N, Beange 197 III, 10. 4. 2 | showed an average intake of 0.13µg/kg bw (EFSA, 2006).~ ~PFOS 198 IV, 12. 10 | Environment Management System ISO 14000 / ISO 14001. ~ ~Use of pesticides~ 199 IV, 12. 10 | Management System ISO 14000 / ISO 14001. ~ ~Use of pesticides~ high~ ~ ~ 200 II, 5. 5. 3 | unprovoked seizures. Epilepsia 43:1402-1409.~Lindsten H, Nystrom 201 II, 5. 5. 1 | EQ-5D. Qual Life Res 15(8):1403-14.~ ~Schmidtke A., Bille-Brahe 202 II, 5. 5. 3 | for stigma. Epilepsia 45:1405-1415.~Jallon P (2004): Mortality 203 IV, 12. 1 | Social security~Regulation 1408/71 Providing for the payment~( 204 II, 5. 5. 3 | seizures. Epilepsia 43:1402-1409.~Lindsten H, Nystrom L, 205 II, 5. 5. 3 | stigma. Epilepsia 45:1405-1415.~Jallon P (2004): Mortality 206 III, 10. 2. 4 | 16p12.2. Diabetologia, 50:1418-1422.~ ~Hoos A, Urist MJ, 207 III, 10. 2. 4 | 2. Diabetologia, 50:1418-1422.~ ~Hoos A, Urist MJ, Stojadinovic 208 II, 5. 5. 3 | sclerosis. N Engl J Med 343:14301438.~Confavreux C, Vukusic 209 III, 10. 2. 1 | Obstetrics and Gynaecology 112:1431–1433.~ ~Kapantais E, Haralambides 210 II, 5. 6. 6 | ability. J Rheumatol 21:1432-1437~Hochberg MC, Chang 211 III, 10. 2. 1 | and Gynaecology 112:1431–1433.~ ~Kapantais E, Haralambides 212 II, 5. 6. 6 | ability. J Rheumatol 21:1432-1437~Hochberg MC, Chang RW, Dwosh 213 II, 5. 5. 3 | smoking and alcohol use in 144 PD patients and 464 matched 214 III, 10. 6. 1 | of Public Health 93(9): 1442-1445.~ ~Currie C, Gabhainn 215 II, 5. 5. 3 | scale (EDSS). Neurology 33:1444-1452.~Larocca et al. Factors 216 II, 5. 11. 3 | New York:McGraw-Hill, 1999:1447-1461.~Boc A. A pilot study 217 II, 5. 9. 4 | environmental factors among 1450 children aged 13- to 14- 218 III, 10. 5. 1 | Journal of Public Health 93(9):1451-1456.~Kim HS, Mccarthy H, 219 II, 5. 11. 3 | York:McGraw-Hill, 1999:1447-1461.~Boc A. A pilot study on 220 III, 10. 2. 1 | adults. Obesity Research 12:14641472.~ ~Boros J, Németh 221 III, 10. 2. 1 | CD004148. DOI: 10.1002/14651858.CD004148.pub3.~ ~Olsson 222 II, 5. 5. 3 | population-based study. Epilepsia 41:1469-1473.~Lhatoo SD, Sander 223 II, 5. 5. 3 | study. Epilepsia 41:1469-1473.~Lhatoo SD, Sander JWAS, 224 II, 5. 8. 7 | Disease Study. Lancet 349: 1498–1504.~ ~Murtagh E, Heaney 225 II, 9. 1. 1 | group of children born 1000-1499g (Platt et al, 2007).~ ~Table 226 II, 9. 1. 1 | a weight at birth below 1500g. VLBW rate among live births 227 II, 5. 8. 7 | Study. Lancet 349: 1498–1504.~ ~Murtagh E, Heaney L, 228 II, 5. 5. 3 | sclerosis. Update. Nervenarzt 77:1506-18. (Article in German)~ 229 II, 5. 5.Int(21)| period 2002-2006, Decision 1513/2002/EC of the European 230 II, 9. 3. 1 | Cancer Inst, 1997. 89(20): p. 1516-23~ ~Makino M, Tsuboi K, 231 II, 5. 2. 6 | randomised trials. Lancet 362: 1527-1535.~Vasan RS, Larson MG, 232 II, 5. 2. 6 | trials. Lancet 362: 1527-1535.~Vasan RS, Larson MG, Leip 233 II, 8. 2. 1 | disabilities.~In a survey of 1542 adults with intellectual 234 II, 5. 2. 7 | cardiovascular disease. Lancet 353:1547-57.~Tunstall-Pedoe H, Vanuzzo 235 II, 5. 8. 7 | cohort. Chest 2005; 127: 1544-1552.~ ~Lindberg A, Eriksson 236 III, 10. 3. 1 | Technical Specification ISO/TS 15666 Acoustics – Assessment of 237 III, 10. 4. 2 | in 1999, to 823 in 2000, 1567 in 2001, 3024 in 2002, 4414 238 IV, 12. 10 | health issues~ high~o Law 1568/1985Health and Safety 239 II, 5. 5. 3 | Psychiatric Association 156th Annual Meeting: Abstract 240 II, 5. 2. 6 | and treatment. JAMA 275: 1571-1576.~Keys A, Aravanis C, 241 II, 5. 8. 7 | Respir. Crit. Care Med. 163:1572-1577.~ ~ ~ 242 II, 5. 5. 3 | PEDIATRICS Vol. 114 No. 6, 1574-1583.~NEDA (National Eating 243 II, 5. 2. 6 | treatment. JAMA 275: 1571-1576.~Keys A, Aravanis C, Blackburn 244 II, 5. 6. 6 | of 10 years. BMJ 320:1577-1578~Petersson IF, Jacobsson 245 II, 5. 5. 3 | PEDIATRICS Vol. 114 No. 6, 1574-1583.~NEDA (National Eating Disorders 246 II, 5. 2. 7 | All-Cause Mortality JAMA 292:1588-1592.~Daviglus ML, Liu K, 247 IV, 11. 6. 5 | Services Research 39(5): 1589-606.~ ~Robinson R, Jakubowski 248 II, 5. 2. 7 | Mortality JAMA 292:1588-1592.~Daviglus ML, Liu K, Pirzada 249 II, 9. 5. 6 | Public Health, 4th ed, p 1596~ ~White AK, Holmes M (2006): 250 IV, 11. 6. 5 | Report 2000." Lancet 356: 1598-1601.~ ~Naylor CD, Iron 251 II, 5. 7. 5 | counties, the so called15a-Vereinbarung".~· In the Czech Republic, 252 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.15b. Lung cancer (ICD9 162) 253 II, 5. 5. 1 | survey in Finland using 15D and EQ-5D. Qual Life Res 254 IV, 11. 6. 5 | 2000." Lancet 356: 1598-1601.~ ~Naylor CD, Iron K et 255 II, 5. 5. 3 | J Neural Transm 112(12):1605-1612.~von Campenhausen S, 256 II, 5. 5. 3 | Neural Transm 112(12):1605-1612.~von Campenhausen S, Bornschein 257 I, 2. 5. 0(3) | PREREL_YEAR_2008_MONTH_12/2-16122008-EN-AP.PDF~ 258 II, 5. 5. 3 | population. Epilepsia 45:1613-1622.~Gallitto G, Serra 259 III, 10. 1. 3 | consequences. Addiction 91(11):1615-1621.~Rosner B (2000): Fundamentals 260 III, 10. 2. 1 | Metabolic Disorders 26:1610-1616.~ ~Savva SC, Kourides Y, 261 III, 10. 2. 1 | http://lib.bioinfo.pl/pmid:16184880~Iceland~The Diet of Icelanders 262 III, 10. 5. 3 | European Heart Journal 27:1610-1619.~Martikainen, P. & Valkonen, 263 III, 10. 1. 3 | consequences. Addiction 91(11):1615-1621.~Rosner B (2000): Fundamentals 264 II, 5. 5. 3 | population. Epilepsia 45:1613-1622.~Gallitto G, Serra S, La 265 II, 9. 3. 1 | carcinoma. Cancer 104(8): 1633-1637~ ~Lim LS, Fitzpatrick 266 III, 10. 2. 1 | British Medical Journal, 316: 1636-42.~ ~Ljung R, Peterson 267 II, 9. 3. 1 | carcinoma. Cancer 104(8): 1633-1637~ ~Lim LS, Fitzpatrick RD ( 268 III, 10. 2. 1 | Alimentaires~INCA~1998-1999~1642~15-92~Individual dietary 269 III, 10. 5. 1 | Health Perspectives, 111:1649–1653.~Cla W (2002): Effect 270 III, 10. 4. 3 | problem. Toxicology Letters 164S: S324-S325~Valent F, et 271 III, 10. 5. 1 | Health Perspectives, 111:1649–1653.~Cla W (2002): Effect of 272 IV, 12. 10 | substance abuse~ High~Decision 1654/11/2006 for approval of 273 II, 5. 11. 7 | publication No. (PHS) 791660. US Department of Health, 274 III, 10. 1. 3 | consequences. Addiction 91(11):1663-1674.~Brady KT, Sonne SC ( 275 III, 10. 1. 3 | consequences. Addiction 91(11):1663-1674.~Brady KT, Sonne SC (1999): 276 II, 5. 5. 3 | Marino. Neurology 37(10):1679-1682.~de Rijk MC, Breteler 277 II, 5. 6. 6 | population. Am J Public Health 87:1680-1682~Reynolds DL, Chambers 278 II, 5. 8. 7 | disease? Chest 2003; 123: 1684-1692.~ ~Horton K (2008): 279 II, 5. 8. 7 | disease? Chest 2003; 123: 1684-1692.~ ~Horton K (2008): The 280 II, 5. 7. 7 | Soc Nephrol 2006 Jun;17(6):1695-702.~ERA-EDTA Registry ( 281 IV, 11. 6. 5 | general practice." BMJ 300: 1698-701.~ ~Kutzin J (1998): 282 III, 10. 2. 4 | diabetes locus on chromosome 16p12.2. Diabetologia, 50:1418- 283 IV, 12. 10 | Way’ was launched on June 16th 2008.~ ~ ~B) Actions adopted 284 III, 10. 2. 1 | prevalence of cannabis among 15-16y-old students~ ~Drug use among 285 III, 10. 5. 1 | analyses of water samples from 1700 public and 3300 private 286 II, 5. 6. 6 | population survey. J Rheumatol 24:1703-1709~Hakala M, Nieminen 287 II, 5. 6. 6 | survey. J Rheumatol 24:1703-1709~Hakala M, Nieminen P, Koivisto 288 III, 10. 2. 4 | J Public Health, 86(12): 1717-1722.~ ~Kononen J, Bubendorf 289 III, 10. 2. 1 | Consumption Survey~BNFCS2004~2004~1723~16-64~24-hour recall~2~General 290 III, 10. 2. 1 | Nutrition Survey~NDNS~2000-2001~1724~19-64~Individual dietary 291 III, 10. 4. 1 | health, NO 10/2005. ISSN 1725-9177.~ ~Clean Air for Europe ( 292 II, 5. 8. 7 | data. Lancet 2006; 367: 1747-1757.~ ~Lundback B, Lindberg 293 III, 10. 2. 1 | study~SISP04~2003 - 2004~1751~16-64~24-hour recall~2~General 294 II, 5. 8. 7 | Lancet 2006; 367: 1747-1757.~ ~Lundback B, Lindberg 295 IV, 12. 10 | public health law~Law 2006.1772 about water and aquatic 296 III, 10. 2. 1 | 2004]. Orvosi Hetilap 146:1781-1789 (in Hungarian).~ ~Rolland-Cachera 297 III, 10. 2. 1 | No 2826/2000, (EC): No 1782/2003 and (EC): No 318/2006 298 II, 9. 2. 7 | Council (2002): Decision No 1786/2002/EC adopting a programme 299 III, 10. 2. 1 | Orvosi Hetilap 146:1781-1789 (in Hungarian).~ ~Rolland-Cachera 300 II, 5. 5. 3 | for management. Lancet 359:1790-1791.~Rutter M, Graham P, 301 II, 5. 5. 3 | management. Lancet 359:1790-1791.~Rutter M, Graham P, Yule 302 II, 5. 14. 3 | GDP, or approximately 1/17th of overall health care expenditures. 303 III, 10. 5. 3 | top incidence rate of app. 1800 per 100,000 is reported 304 IV, 11. 1. 3 | systems dates back to the 1800s when Florence Nightingale 305 III, 10. 2. 5 | adults. N Engl J Med 2005;353:1802-909.~ ~Bastra L, Hadders-Algra 306 III, 10. 3. 1 | uv/health/solaruvradfull_180706.pdf)~Mcelroy Ja, Egan Km, 307 IV, 11. 6. 5 | methods." The Lancet 361: 1817-20.~ ~Navarro D (2000): " 308 II, 5. 7. 7 | Transplant 2003 Sep;18(9):1824-33.~Stevens PE, O'donoghue 309 II, 5. 5. 3 | Aeolian islands. Epilepsia 46:1828-1835.~Harris EC, Barraclough 310 II, 5. 2. 7 | case fatality?. Stroke 34:1833-1841~Thom TJ (1989): International 311 II, 5. 2. 6 | deaths. Lancet 370: 1829-1839.~Robinson JG, Smith B, Maheshwari 312 II, 5. 2. 7 | fatality?. Stroke 34:1833-1841~Thom TJ (1989): International 313 II, 9. 3. 3 | experience. Lancet 358(9296): 1843-1850.~Wellings K, Collumbien 314 II, 9. 3. 3 | pregnancy strategy: Lancet 368:1846-1848~ ~ ~ 315 II, 9. 3. 3 | strategy: Lancet 368:1846-1848~ ~ ~ 316 II, 5. 2. 6 | analysis. J Am Coll Cardiol 46: 1855-1862.~Stamler J, Wentworth 317 II, 5. 2. 6 | Am Coll Cardiol 46: 1855-1862.~Stamler J, Wentworth D, 318 III, 10. 5. 2 | British Journal of Cancer. 82, 1863-1866.~ ~Department of the 319 II, 9. 3. 3 | ethnic minorities. Aids 18 :1867-73.~Dubois-Arber F, Jeannin 320 II, 5. 5. 3 | in treated schizophrenia: 1875-1924 and 1994-1998 cohorts 321 IV, 12. 10 | and health~ high~Decision 1877/12/2005 National plan of 322 III, 10. 4. 2 | Commission regulation (EC) 1882/2006 lays down the sampling 323 III, 10. 4. 2 | Commission regulation (EC) 1883/2006 lays down the sampling 324 II, 5. 7. 7 | Transplant 2006 Jul;21(7):1899-905.~Meisinger C, Doring 325 IV, 12. 10 | include the following:~ ~Under 18s - A Report of the Working~ 326 IV, 12. 10 | the end of life (ELV)” of 18th September 2000”~Alternative 327 II, 5. 5. 3 | epidemiologic survey. Neurology 44:19011907.~Brønnum-Hansen H, 328 II, 5. 2. 6 | prospective studies. Lancet 360: 1903-1913.~Kannel WB (1985). 329 II, 5. 6. 3 | with rates in men of 4 and 1909 respectively (Cooper and 330 II, 5. 2. 6 | studies. Lancet 360: 1903-1913.~Kannel WB (1985). Lipids, 331 II, 5. 8. 7 | stop-smoking rate. Chest 2003; 123: 1916-1923.~ ~Gudmundsson G, Gislason 332 II, 5. 5. 3 | project. Neurology 43(10):1918-1926.~van de Vijver DA, 333 II, 5. 8. 3 | cohort of patients born in 1919 to 1929, 1934 to 1935 and 334 II, 5. 8. 7 | rate. Chest 2003; 123: 1916-1923.~ ~Gudmundsson G, Gislason 335 II, 5. 5. 3 | project. Neurology 43(10):1918-1926.~van de Vijver DA, Roos 336 II, 5. 8. 3 | patients born in 1919 to 1929, 1934 to 1935 and 1949 to 337 II, 5. 8. 3 | patients born in 1919 to 1929, 1934 to 1935 and 1949 to 1950 338 I, 3. 3 | today’s survivors born in 1940. Some slight indentation 339 II, 6. 3. 7 | biological warfare agent since 1941.~ ~Over the last 10 years, 340 II, 5. 5. 3 | Cross-sectional~105~12.0~8.7~Alstrom, 1942 (*)~ ~NC/EC~Prevalent cohort~ 341 II, 5. 5. 3 | conceptualised as ASDs.~In 1943 Leo Kanner described Infantile 342 II, 5. 8. 3 | to 1929, 1934 to 1935 and 1949 to 1950 in Northern Sweden, 343 III, 10. 6. 1 | Arch Intern Med 167(18):1951-7.~ ~Ganster DC, Victor 344 II, 5. 5. 3 | Finnish cohorts born from 1954 to 1965. Archives of General 345 II, 9. 5. 6 | Foundation: Findings Ref 1959: Characteristics of care 346 II, 9. 3. 1 | consensus.nih.gov/1992/1992Impotence091html.htm~ ~Niederlaender E (2006): 347 II, 9. 4. 5 | going to invest more than €1bn on research into new technologies 348 II, 9. 5. 3 | 20 minutes in Sweden to 1h:05 in Slovenia. Women have 349 III, 10. 2. 4 | syndrome locus on chromosome 1p36.13 and a type 2 diabetes 350 III, 10. 4. 2 | Tolerable daily intake) of 0.1µg PFOS/kg body weight (BfR 351 II, 5. 5. 3 | europarkinson.net/download/20040114EuroPa_moving_along.pdf~Eurostat ( 352 III, 10. 2. 1 | 2005; Aromaa and Koskinen, 2004Direction of Health, 2004; do Carmo 353 -, 1 | Commission (Grant Agreement n. 2005115) (ii) produced through a 354 IV, 12. 10 | the Council of 15 February 2006concerning the management of bathing 355 III, 10. 2. 1 | Health Organization (WHO) (2006f) Regional Office for Europe: 356 III, 10. 1. 3 | framtidsstudier.se/filebank/files/20080109$110739$fil$mZ8UVQv2wQFShMRF6cuT. 357 III, 10. 6. 1 | InformationSources/Publications/Catalogue/20080617_1.~ ~De Vogli R, Chandola 358 III, 10. 5. 1 | et al, 2006; Zhao et al, 2008b). Recently, there has been 359 III, 10. 4. 2 | policy~Admission policy~WHO, 200a; Barlow et al.,~2002~Substances 360 II, 5. 4. 1 | hyperglycaemia 11.1 mmol/l (200mg/dl) in a random sample or 361 III, 10. 3. 1 | ranges will be completed by 2018, at an overall cost of around 362 III, 10. 4. 5 | the EU's marine waters by 2021 and to protect the resource 363 III, 10. 3. 2 | Abschlussbericht Project 20261218/03 AktionsprogrammUmwelt 364 II, 9. 4. 1 | will increase to 52.3 in 2028. These demographic changes 365 IV, 12. 10 | Ministerial Decision 37591/2031/2003.~In compliance with 366 II, 5. 7. 7 | Soc Nephrol 2006 Jul;17(7):2034-47.~ ~ 367 IV, 12. 10 | of the Council Directive 2037/2000 concerning the substances 368 II, 5. 5. 2 | in 2020 and 81 million by 2040. These predictions are based 369 I, 3. 3 | growth rates from 2005 to 2049. Their old-age-dependency 370 III, 10. 2. 1 | Obesity (Silver Spring): 14:2054-2063.~ ~Wang Y, Lobstein 371 III, 10. 2. 1 | Silver Spring): 14:2054-2063.~ ~Wang Y, Lobstein T (2006): 372 II, 5. 8. 7 | Program. Chest 2005; 128: 2068-2075.~ ~Soriano JB, Visick 373 III, 10. 4. 2 | Commission (2005): Decision No. 2073/2005/CE of 15 November 2005 374 II, 5. 8. 7 | Program. Chest 2005; 128: 2068-2075.~ ~Soriano JB, Visick GT, 375 IV, 12. 10 | of the Council Directive 2092/91 concerning the biological 376 III, 10. 2. 1 | Nutrition Survey~ ~1997~2094~19-65~24-hour recall~1~General 377 II, 5. 8. 7 | primary care. Chest 2005; 128: 2099-2107.~ ~Soriano JB, Maier 378 II, 9. 2. 7 | 22social%20and%20cultural%20aspects%20of%20drinking%22 ] (accessed 379 IV, 12. 10 | the employer’s duty(1996)~§20b SGB V; Act on prevention 380 III, 10. 2. 1 | conferences/6gchp/hpr_050829_%20BCHP.pdf].~ ~World Health Organization ( 381 II, 7. 7 | EE9D475AA6DAF58BC125747200411F14/$file/Implementation%20Council%20Recom.pdf]~ ~World Health 382 II, 9. 2. 7 | pdf#search=%22social%20and%20cultural%20aspects%20of%20drinking% 383 II, 5. 4. 8 | Definition%20and%20diagnosis%20of%20diabetes_new.pdf] (report online, 384 II, 5. 4. 8 | publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf] ( 385 II, 9. 2. 7 | 20cultural%20aspects%20of%20drinking%22 ] (accessed 12.01.07)~ ~ 386 II, 9. 4. 7 | healthyageing.nu/upload/pdf/Chapters%20from%20the%20report/Recommendations% 387 III, 10. 2. 1 | consume on average more than 20g alcohol per day and men 388 III, 10. 2. 1 | Lancet, 2007; 369: 2015-20Martinet Y, Bohadana A, Fagerström 389 II, 9. 4. 7 | 20report/Recommendations%20utan%20omslag.pdf].~The European Men’s 390 II, 7. 7 | Implementation%20Council%20Recom.pdf]~ ~World Health Organization ( 391 II, 9. 4. 7 | pdf/Chapters%20from%20the%20report/Recommendations%20utan%20omslag. 392 II, 5. 11. 3 | occurring in housewives in their 20s and occupational hand eczema 393 II, 9. 4. 7 | upload/pdf/Chapters%20from%20the%20report/Recommendations% 394 II, 9. 4. 7 | 20report/Recommendations%20utan%20omslag.pdf].~The European 395 III, 10. 5. 1 | classroom temperature from 25 to 20°C increased speed at different 396 II, 5. 9. FB | Children (ALSPAC), performed on 2100 British children, reported 397 II, 5. 8. 7 | care. Chest 2005; 128: 2099-2107.~ ~Soriano JB, Maier WC, 398 III, 10. 2. 4 | metabolic syndrome. Obes Res, 13:2122-2131.~ ~Torhorst J, Bucher 399 II, 9. 3. 3 | health and rights (2001/2128 (INI)). Official Journal 400 III, 10. 2. 4 | syndrome. Obes Res, 13:2122-2131.~ ~Torhorst J, Bucher C, 401 II, 5. 7. 7 | Soc Nephrol 2005 Jul;16(7):2134-40.~Levey AS, Bosch JP, 402 II, 5. 4. 3 | between 21 (Cyprus) and 2135 (Austria), with a median 403 II, 8. 2. 1 | of children (altogether 21397 individuals) in Northern 404 II, 5. 4. 8 | retrieveFile?instanceid=9&itemid=2140&style=home]~(report online, 405 II, 5. 5. 3 | Study. Neurology 45(12):2143-2146.~de Rijk MC, Tzourio 406 III, 10. 4. 3 | standards. Science 296: 2145-2146.~The United Nations 407 IV, 12. 10 | o Ministerial Decision 21475/4707 (published in 1998) 408 III, 10. 3. 2 | industrial chemicals. Lancet 368, 2167-2178.~ ~Westfälisches Institut 409 III, 10. 2. 1 | EC): No 2200/96, (EC): No 2201/96, (EC): No 2826/2000, ( 410 III, 10. 2. 1 | repealing Regulation (EC): No 2202/96.~[http://eur-lex.europa. 411 II, 9. 5. 6 | 2005 (Vol. 61) (No. 10) 2221-2232~Heinrich G A (2000): 412 II, 5. 5. 3 | disease. Neurology 43(11):2227-2229.~Gorell JM, Rybicki 413 II, 5. 5. 3 | disease. Neurology 43(11):2227-2229.~Gorell JM, Rybicki BA, 414 II, 9. 5. 6 | Vol. 61) (No. 10) 2221-2232~Heinrich G A (2000): Affluence 415 III, 10. 4. 2 | Commission Regulation (EC) No 2245/2003 and Commission Regulation ( 416 III, 10. 2. 4 | endpoints. Am J Pathol, 159:2249-2256.~ ~UNESCO (1997): Universal 417 III, 10. 2. 4 | endpoints. Am J Pathol, 159:2249-2256.~ ~UNESCO (1997): Universal 418 II, 9. 3. 1 | 2007:2) ISBN 978-952-00-2269-3 (paperback) ISBN 978-952- 419 II, 9. 3. 1 | paperback) ISBN 978-952-00-2270-9 (PDF)~ ~Mental Health 420 II, 5. 7. 7 | Am Soc Nephrol 2006; 17:2275-84.~Hallan SI, Dahl K, Oien 421 III, 10. 5. 2 | www.biomedcentral.com/1471-2296/6/16] (accessed on 19 September 422 II, 5. 5. 3 | community-based study. Brain 123:2297-2305.~Singer E (1973): Social 423 II, 9. 2. 7 | social_drinking.pdf#search=%22social%20and%20cultural%20aspects% 424 II, 5. 5. 3 | community-based study. Brain 123:2297-2305.~Singer E (1973): Social 425 III, 10. 5. 2 | in New Zealand (based on 232 studies / papers etc.) came 426 II, 5. 2. 7 | stroke project. Stroke 33:2367-2375.~Tunstall-Pedoe H, 427 II, 9. 3. 1 | Internal Medicine, 166: 2395 – 2402. Cited by Cancer 428 III, 10. 4. 2 | With regard to Article 23f and 34 of Regulation (EC) 429 II, 5. 5. 3 | Poster presentation at 23rd European Congress for the 430 II, 9. 3. 1 | Internal Medicine, 166: 2395 – 2402. Cited by Cancer Help UK (htt ~ ~ 431 II, 5. 5. 3 | focus. Acta Neurol Scand 88:241-246.~Grytten N, Glad SB, 432 II, 5. 4. 8 | Ugeskr Laeger. 18;169(25):2432-4 [Article in Danish]~EUCID 433 IV, 12. 10 | limits of poverty.~o Law 2434/1996 established the Benefit 434 II, 5. 5. 3 | Teruel, Spain. J Neurol 244:182-185.~Mor u T, eaManceau 435 IV, 12. 10 | Common Ministerial Decision 245090/11.1.2006 for determining 436 II, 5. 9. 7 | Suppl 1):S2 doi:10.1186/1471-2466-6-S1-S2).~ ~Jarvis D, Luczynska 437 II, 5. 5. 3 | comparison Br J Psychiatry 187: 248-255.~Glynn SM (2003): Psychiatric 438 II, 9. 5. 6 | Biomarkers Prev. 2006 Dec;15(12):2494-501~ ~Middle C, Johnson 439 II, 5. 8. 3 | present in 10.4% of the 2497 subjects with different 440 II, 5. 7. 2 | ERA-EDTA (Barcelona, 21st - 24th June 2007) (Zoccali and 441 II, 5. 9. 3 | 44900 had asthma diagnosis, 25100 received treatment from 442 II, 5. 5. 3 | ECA) Study. JAMA 264 (19):2511-2518.~Saha S, Chant D, McGrath 443 II, 5. 5. 3 | Study. JAMA 264 (19):2511-2518.~Saha S, Chant D, McGrath 444 III, 10. 2. 1 | Science and Medicine, 58: 2523-35.~ ~Ditter SM, Elder RW, 445 IV, 12. 10 | for Pensioners (EKAS); law 2556/1997 enlarged the group 446 II, 5. 7. 7 | the JNC 7 report. JAMA 19):2560-72.~Cirillo M, Laurenzi 447 II, 5. 7. 7 | Nephrol 2003 Oct;14(10):2573-80.~Loucks EB, Rehkopf DH, 448 II, 9. 5. 6 | health. Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (2004): 449 II, 5. 2. 5 | European Union - 950/042586 Council Meeting1 and 450 III, 10. 4. 2 | public consultation closed on 25th March.~ ~· Fate of pesticides ( 451 II, 9. 5. 6 | Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (2004): Towards 452 II, 7. 4. 1 | age group is estimated as 26000 cases in the EU27. For every 453 II, 5. 8. 3 | Masa et al, 2004) and 1 261€ in Italy.~ ~An analysis 454 III, 10. 5. 2 | org/document/61/0,3343,en_2649_37429_38690301_1_1_1_37429, 455 III, 10. 2. 1 | among adults~NORKOST~1997~2672~16-79~Food Frequency Questionnaire~ ~ ~ 456 IV, 12. 10 | eligible pensioners, while law 2676/1999 increased the amount 457 IV, 12. 10 | comparison with the previous code 2696/1999) makes stricter the 458 II, 5. 7. 5 | chronic diseases. On September 26th 2007, after a special convention 459 IV, 12. 10 | in Greece with the law N. 2716/99 and the national program 460 IV, 12. 10 | Ministerial Decision 50910/2727/2003Measures and terms 461 II, 5. 4. 8 | prevention of type 2 diabetes, 2733rd Employment, Social Policy, 462 III, 10. 1. 3 | Research. Circulation 114:2739-2752.~Marshall JR (1994): 463 III, 10. 1. 3 | Research. Circulation 114:2739-2752.~Marshall JR (1994): The 464 II, 5. 6. 3 | among all respondents (n=2755) in Sweden~ ~ ~Figure 5. 465 II, 5. 7. 7 | Kidney Int 2005 Dec;68(6):2801-8.~Hallan SI, Coresh J, 466 II, 5. 2. 6 | Trial (MRFIT). JAMA 256: 2823-2828.~Turnbull F; Blood 467 III, 10. 2. 1 | EC): No 2201/96, (EC): No 2826/2000, (EC): No 1782/2003 468 II, 5. 2. 6 | MRFIT). JAMA 256: 2823-2828.~Turnbull F; Blood Pressure 469 III, 10. 2. 5 | factors. Diabetologia 2006;49:2853 - 8~ ~Gale CR, Martyn CN ( 470 III, 10. 1. 3 | Alcohol Clin Exp Res 22(7):285S-298S.~Thompson JC (2005): The 471 II, 5. 11. 3 | Contact Dermatitis,1985;13:289293.~C Lidén, M Bruze, T 472 II, 5. 4. 8 | and its morbidity HMP SI2.2895.39~Gudbjörnsdottir S, Cederholm 473 III, 10. 4. 2 | food supplements.~ ~On 28th January 2002 the European 474 IV, 12. 10 | Common Ministerial Decision 29407/3508/2002 in compliance 475 II, 5. 5. 3 | Pharmacoeconomics 14(3):299-312.~Dorsey ER, Constantinescu 476 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.29a. All cancers (ICD9 140-172, 477 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.29b. All cancers (ICD9 140-172, 478 III, 10. 4. 2 | and distribution.~ ~On the 29th April 2004, Regulation EC 479 II, 9. 1. 2 | Sante Publique, Vol 53, pp 2S87-2S95.~Dolk H, Vrijheid, Scott 480 II, 5. 5. 3(26)| A5-0451/3003 European Parliament Resolution 481 III, 10. 2. 1 | Scandinavian countries, 300µg/d of folate are recommended 482 IV, 12. 1 | fundamental freedoms’.~ ~Art. 300-302 (Closing of agreements with 483 III, 10. 4. 2 | 823 in 2000, 1567 in 2001, 3024 in 2002, 4414 in 2003, 5562 484 II, 5. 6. 3 | aged under 35,rising to 3032/100,000 person-years in 485 IV, 12. 10 | High~ Ministerial Decision 30528/ (23.3.2005) concerning 486 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.30a. Stomach cancer (ICD9 151) 487 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.30b. Stomach cancer (ICD9 151) 488 II, 5. 2. 4 | obesity (defined as BMI 30kg/m2 ) in 27 EU countries 489 II, 8. 1. 5 | European Commission adopted on 30th of October 2003 a Communication 490 II, 5. 10. 7 | of the European Union L 310, 28.11.2007, pp. 1114.~ ~ 491 II, 5. 7. 7 | analysis. JAMA 2003;290(23):3101-14.~Chadban SJ, Briganti 492 III, 10. 4. 2(27)| Document No SANCO/2007/3131,31/10/2007.~ 493 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.31a. Colorectal cancer (ICD9 494 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.31b. Colorectal cancer (ICD9 495 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32000L0013:EN:HTML].~European Council ( 496 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32001L0015:EN:HTML]~ ~European Commission ( 497 II, 7. 7 | product safety (CELEX-Nr. 32001L0095).~ ~EuroSafe (2008): Injuries 498 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32002L0046:EN:HTML]~European Council ( 499 II, 7. 7 | July 18, 2007 (CELEX-Nr. 32007H0718).~ ~European Commission ( 500 IV, 12. 10 | 655 respectively.~o Law 3227/2004 Concerning the duties